Wedbush reaffirmed their buy rating on shares of Allena Pharmaceuticals (NASDAQ:ALNA) in a research report report published on Monday. Wedbush also issued estimates for Allena Pharmaceuticals’ Q4 2017 earnings at ($0.28) EPS, Q1 2018 earnings at ($0.37) EPS, Q2 2018 earnings at ($0.37) EPS, Q3 2018 earnings at ($0.37) EPS, Q4 2018 earnings at ($0.37) EPS, FY2018 earnings at ($1.48) EPS, FY2019 earnings at ($1.88) EPS, FY2020 earnings at ($2.09) EPS and FY2021 earnings at ($2.59) EPS.

“We reiterate our Underperform rating and $37 price target post 3Q:17 and after speaking with management. We continue to see minimal value from Eagle’s pipeline and expect the company to acquire an asset.”,” Wedbush’s analyst commented.

Several other equities research analysts also recently commented on ALNA. Cowen assumed coverage on shares of Allena Pharmaceuticals in a research report on Monday, November 27th. They set an outperform rating for the company. Jefferies Group assumed coverage on shares of Allena Pharmaceuticals in a research report on Monday, November 27th. They set a buy rating and a $22.00 target price for the company. Finally, Credit Suisse Group assumed coverage on shares of Allena Pharmaceuticals in a research report on Monday, November 27th. They set an outperform rating and a $22.00 target price for the company.

Shares of Allena Pharmaceuticals (NASDAQ:ALNA) opened at $10.32 on Monday. The company has a current ratio of 4.83, a quick ratio of 4.83 and a debt-to-equity ratio of -0.09. Allena Pharmaceuticals has a 52-week low of $8.66 and a 52-week high of $15.40.

In other news, Director James N. Topper acquired 500,000 shares of Allena Pharmaceuticals stock in a transaction on Monday, November 6th. The stock was acquired at an average cost of $14.00 per share, with a total value of $7,000,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Bessemer Venture Partners Vii acquired 36,000 shares of Allena Pharmaceuticals stock in a transaction on Monday, November 6th. The stock was purchased at an average cost of $14.00 per share, with a total value of $504,000.00. The disclosure for this purchase can be found here.

ILLEGAL ACTIVITY NOTICE: “Allena Pharmaceuticals (ALNA) Earns “Buy” Rating from Wedbush” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/21/allena-pharmaceuticals-alna-earns-buy-rating-from-wedbush.html.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.